[HTML][HTML] Analysis of RAS gene mutations in adverse events during first induction chemotherapy in childhood acute lymphoblastic leukemia
T Chen, N Wei, W Lv, L Qu, H Liu - Translational Pediatrics, 2023 - ncbi.nlm.nih.gov
Background The rat sarcoma virus (RAS) pathway controls cell proliferation, differentiation,
and apoptosis, which have been implicated in the pathogenesis of various hematological …
and apoptosis, which have been implicated in the pathogenesis of various hematological …
Monocytic Differentiation in Acute Myeloid Leukemia Cells: Diagnostic Criteria, Biological Heterogeneity, Mitochondrial Metabolism, Resistance to and Induction by …
Ø Bruserud, F Selheim… - International Journal of …, 2024 - mdpi.com
We review the importance of monocytic differentiation and differentiation induction in non-
APL (acute promyelocytic leukemia) variants of acute myeloid leukemia (AML), a …
APL (acute promyelocytic leukemia) variants of acute myeloid leukemia (AML), a …
Venetoclax, a new player in the treatment of children with high-risk myeloid malignancies?
Venetoclax selectively inhibits BCL-2 and restores apoptotic signaling of hematological
malignant cells. Venetoclax in combination with hypomethylating and low-dose cytotoxic …
malignant cells. Venetoclax in combination with hypomethylating and low-dose cytotoxic …
Enhanced venetoclax delivery using L-phenylalanine nanocarriers in acute myeloid leukemia treatment
L Zhang, L Lei, Z Zhao, G Yang, K Wang, L Wang… - Chinese Chemical …, 2024 - Elsevier
Abstract Venetoclax (Vene), a BCL-2 inhibitor, is widely used as a chemotherapeutic drug in
acute myeloid leukemia (AML). However, its treatment specificity for leukemia cells is limited …
acute myeloid leukemia (AML). However, its treatment specificity for leukemia cells is limited …
[HTML][HTML] The growing role of the BH3 mimetic drug Venetoclax in the therapy of acute myeloid leukemia
E Pelosi, G Castelli, U Testa - Mediterranean Journal of …, 2022 - ncbi.nlm.nih.gov
Despite recent progress, acute myeloid leukemia (AML) remains a disease associated with
poor prognosis, particularly in older AML patients unfit to tolerate intensive chemotherapy …
poor prognosis, particularly in older AML patients unfit to tolerate intensive chemotherapy …
[HTML][HTML] Application of omics in the diagnosis, prognosis, and treatment of acute myeloid leukemia
Z Zhang, J Huang, Z Zhang, H Shen, X Tang, D Wu… - Biomarker …, 2024 - Springer
Acute myeloid leukemia (AML) is the most frequent leukemia in adults with a high mortality
rate. Current diagnostic criteria and selections of therapeutic strategies are generally based …
rate. Current diagnostic criteria and selections of therapeutic strategies are generally based …
[HTML][HTML] Allosteric SHP2 inhibition increases apoptotic dependency on BCL2 and synergizes with venetoclax in FLT3-and KIT-mutant AML
B Popescu, C Stahlhut, TC Tarver, S Wishner… - Cell Reports …, 2023 - cell.com
Mutations in the receptor tyrosine kinases (RTKs) FLT3 and KIT are frequent and associated
with poor outcomes in acute myeloid leukemia (AML). Although selective FLT3 inhibitors …
with poor outcomes in acute myeloid leukemia (AML). Although selective FLT3 inhibitors …
[HTML][HTML] Real-world experience with selinexor-containing chemotherapy-free or low-dose chemotherapy regimens for patients with relapsed/refractory acute myeloid …
X Tong, J Jin, B Xu, S Su, L Li, M Li, Y Peng… - Frontiers in …, 2023 - frontiersin.org
Introduction: Treatment of relapsed or refractory acute myeloid leukemia (R/R AML) and
myeloid sarcoma (MS) has presented challenges for decades. Studies on selinexor in …
myeloid sarcoma (MS) has presented challenges for decades. Studies on selinexor in …
[HTML][HTML] Pharmacological Inhibition of PIP4K2 Potentiates Venetoclax-Induced Apoptosis in Acute Myeloid Leukemia
Phosphatidylinositol-5-phosphate 4-kinase type 2 (PIP4K2) protein family members
(PIP4K2A, PIP4K2B, and PIP4K2C) participate in the generation of PIP 4, 5 P2, which acts …
(PIP4K2A, PIP4K2B, and PIP4K2C) participate in the generation of PIP 4, 5 P2, which acts …
[HTML][HTML] Dysregulation of plasma circulating microRNAs in all-cause and cause-specific cancers: the Rotterdam Study
Y Shuai, X Zhang, BDA Lavrijssen, MA Ikram… - Biomarker …, 2024 - Springer
MicroRNAs (miRNAs) are small non-coding RNAs involved in post-transcriptional regulation
of gene expression. Mounting evidence underscores the dysregulation of miRNAs to be …
of gene expression. Mounting evidence underscores the dysregulation of miRNAs to be …